University of Michigan

Eastern Michigan University

University System of Maryland

Cory Emal

Daniel Lawrence

Shih-Hon Li

Mark Warnock

Enming Joe Su

Jacqueline Cale

Ashley Reinke

Dudley Strickland

Jeanne Ann Cupp

Gregory Abernathy

Daniel A Lawrence

Provided herein are plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use

The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

Plasminogen activator inhibitor-1 inhibitors and methods of use thereof

The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.

Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism

Growing community of inventors

Ann Arbor, MI, United States of America

Cory Emal